Orasure Technologies (OSUR) 6.40 $OSUR
OraSure Technologies Has Returned 13.3% Since SmarTrend Recommendation (OSUR)
Comtex SmarTrend(R) - Fri May 09, 9:28AM CDT
SmarTrend identified a Downtrend for OraSure Technologies (NASDAQ:OSUR) on April 10th, 2014 at $6.90. In approximately 4 weeks, OraSure Technologies has returned 13.33% as of today's recent price of $5.98.
OraSure Announces 2014 First Quarter Financial Results
GlobeNewswire - Wed May 07, 3:00PM CDT
OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the first quarter of 2014.
Cervical Cancer - Pipeline Review, H1 2014: 48 Company and 82 Drugs Profiled
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpfpds/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - 3SBio Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Amorfix Life Sciences Ltd. - Antigen Express, Inc. - ApoVax, Inc. - Arbor Vita Corporation - Azaya Therapeutics Incorporated - Bionor Pharma ASA - CEL-SCI Corporation - CZ BioMed Corp - Centre de Regulacio Genomica - Chong Kun Dang Pharmaceutical Corp. - Coridon Pty Ltd - Daiichi Sankyo Company, Limited - Dendreon Corporation - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Formune S.L. - Genetic Immunity, Inc - Genexine, Inc. - Genmab A/S - Genticel - Gilead Sciences, Inc. - GlaxoSmithKline plc - Helix BioPharma Corp. - ISA Pharmaceuticals B.V. - Indian Immunologicals Limited - LondonPharma Ltd - Med Discovery SA Drug Profiles: - hot water extract of mycobacterium tuberculosis - bevacizumab - (tegafur gimeracil oteracil potassium) - etirinotecan pegol - interferon alpha-2b - ADXS-HPV - ProCervix - hot water extract of mycobacterium tuberculosis - celecoxib - Triapine - exatecan mesylate - buparlisib hydrochloride - nimotuzumab - GSK-2141795 trametinib - TG-4001 - pazopanib hydrochloride - CIGB-228 Vaccine - CIGB-300 - nedaplatin [paclitaxel albumin-bound] - TA-HPV Vaccine - mapatumumab - artemether - HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - ISA-101 - HuMax-TF ADC - PDS-0101 - docetaxel liposomal - Leukocyte Interleukin Injection - everolimus - GSK-2256098 For more information visit http://www.researchandmarkets.com/research/wp...cal_cancer
ANY LAB TEST NOW(R) Announces Intercept Oral Fluid Drug Testing Is Now Offered
PRWeb - Tue Apr 29, 8:06AM CDT
ANY LAB TEST NOW(R) is proud to announce that OraSure Technologies' Intercept oral fluid specimen collection method for drug testing, is now available in all Texas locations. Oral fluid collection using the Intercept device is a more accurate specimen to use for drug testing when determining recent drug use. As the only oral fluid drug testing system cleared for nine drugs, Intercept is also the only lab-based saliva test on the market with more than 10 years of proven performance and over 15 million samples tested with accurate, reliable results.
OraSure Technologies Earnings Conference Call Invitation
GlobeNewswire - Tue Apr 22, 5:00AM CDT
2014 First Quarter Earnings Conference Call
Analyst Bullish On Medical Research, Equipment Stocks
at Investor's Business Daily - Tue Apr 08, 12:33PM CDT
A new analyst report from Cowen & Co. offers an upbeat assessment of medical research and equipment stocks ahead of first-quarter earnings, thanks to improving end markets. In his report on the Life Sciences and Diagnostic Tools sectors on Tuesday,...
OraSure Technologies Up 15.5% Since SmarTrend Uptrend Call (OSUR)
Comtex SmarTrend(R) - Fri Apr 04, 9:33AM CDT
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on February 18th, 2014 at $6.74. In approximately 2 month, OraSure Technologies has returned 15.52% as of today's recent price of $7.78.
OraSure Technologies' Debra Fraser-Howze Receives 2014 "Top Blacks in Healthcare" Award
GlobeNewswire - Fri Apr 04, 5:27AM CDT
OraSure Technologies, Inc. (Nasdaq:OSUR) is proud to announce that Debra Fraser-Howze, the Company's Senior Vice President of Government and External Affairs, received a 2014 "Top Blacks in Healthcare" Award from BlackDoctor.org in partnership with Johns Hopkins Center for Health Disparities Solutions.
4 Stocks Under $10 Moving Higher
at The Street - Fri Mar 28, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
OraSure Technologies Up 21.2% Since SmarTrend Uptrend Call (OSUR)
Comtex SmarTrend(R) - Thu Mar 27, 5:16PM CDT
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on February 18th, 2014 at $6.74. In approximately 1 month, OraSure Technologies has returned 21.16% as of today's recent price of $8.16.
SQI Diagnostics Signs Commercial Agreement with Global Pharma Customer
PR Newswire - Thu Mar 20, 2:26PM CDT
SQI to Develop Custom 21-Plex Protein Microarray for Drug Epitope Mapping -
OraSure Technologies Shares Up 18.6% Since SmarTrend's Buy Recommendation (OSUR)
Comtex SmarTrend(R) - Thu Mar 20, 11:13AM CDT
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on February 18th, 2014 at $6.74. In approximately 1 month, OraSure Technologies has returned 18.63% as of today's recent price of $7.99.
Uptrend Call Working As OraSure Technologies Stock Rises 19.2% (OSUR)
Comtex SmarTrend(R) - Thu Mar 13, 10:05AM CDT
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on February 18th, 2014 at $6.74. In approximately 3 weeks, OraSure Technologies has returned 19.23% as of today's recent price of $8.03.
Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and Financial Reports - Analyst Notes on Arrowhead, ANI, OraSure, Rigel, and Foundation Medicine
PR Newswire - Mon Mar 10, 11:30AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), OraSure Technologies, Inc. (NASDAQ: OSUR), Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Ways You Can Be a Better Health-Care Investor Than Warren Buffett
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 09, 1:03PM CDT
Behind only three other people on this planet -- Bill Gates, Carlos Slim, and Amancio Ortega -- stands Warren Buffett with $58.2 billion in accumulated wealth, according to Forbes ' latest rankings of the world's richest people. Buffett, perhaps...
Why OraSure Technologies, Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 05, 4:07PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of OraSure Technologies , a marketer of...
OraSure Technologies to Present at the Cowen & Company 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 26, 5:00AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. 34 Annual Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet.
OraSure Technologies to Present at the Raymond James 35th Annual Institutional Investors Conference
GlobeNewswire - Mon Feb 24, 5:12AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Raymond James 35 Annual Institutional Investors Conference in Orlando, Florida. The conference will be simultaneously webcast over the Internet.
OraSure Technologies Has Returned 13.3% Since SmarTrend Recommendation (OSUR)
Comtex SmarTrend(R) - Fri May 09, 9:28AM CDT
SmarTrend identified a Downtrend for OraSure Technologies (NASDAQ:OSUR) on April 10th, 2014 at $6.90. In approximately 4 weeks, OraSure Technologies has returned 13.33% as of today's recent price of $5.98.
OraSure Announces 2014 First Quarter Financial Results
GlobeNewswire - Wed May 07, 3:00PM CDT
OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the first quarter of 2014.
Cervical Cancer - Pipeline Review, H1 2014: 48 Company and 82 Drugs Profiled
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpfpds/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - 3SBio Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Amorfix Life Sciences Ltd. - Antigen Express, Inc. - ApoVax, Inc. - Arbor Vita Corporation - Azaya Therapeutics Incorporated - Bionor Pharma ASA - CEL-SCI Corporation - CZ BioMed Corp - Centre de Regulacio Genomica - Chong Kun Dang Pharmaceutical Corp. - Coridon Pty Ltd - Daiichi Sankyo Company, Limited - Dendreon Corporation - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Formune S.L. - Genetic Immunity, Inc - Genexine, Inc. - Genmab A/S - Genticel - Gilead Sciences, Inc. - GlaxoSmithKline plc - Helix BioPharma Corp. - ISA Pharmaceuticals B.V. - Indian Immunologicals Limited - LondonPharma Ltd - Med Discovery SA Drug Profiles: - hot water extract of mycobacterium tuberculosis - bevacizumab - (tegafur gimeracil oteracil potassium) - etirinotecan pegol - interferon alpha-2b - ADXS-HPV - ProCervix - hot water extract of mycobacterium tuberculosis - celecoxib - Triapine - exatecan mesylate - buparlisib hydrochloride - nimotuzumab - GSK-2141795 trametinib - TG-4001 - pazopanib hydrochloride - CIGB-228 Vaccine - CIGB-300 - nedaplatin [paclitaxel albumin-bound] - TA-HPV Vaccine - mapatumumab - artemether - HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - ISA-101 - HuMax-TF ADC - PDS-0101 - docetaxel liposomal - Leukocyte Interleukin Injection - everolimus - GSK-2256098 For more information visit http://www.researchandmarkets.com/research/wp...cal_cancer
ANY LAB TEST NOW(R) Announces Intercept Oral Fluid Drug Testing Is Now Offered
PRWeb - Tue Apr 29, 8:06AM CDT
ANY LAB TEST NOW(R) is proud to announce that OraSure Technologies' Intercept oral fluid specimen collection method for drug testing, is now available in all Texas locations. Oral fluid collection using the Intercept device is a more accurate specimen to use for drug testing when determining recent drug use. As the only oral fluid drug testing system cleared for nine drugs, Intercept is also the only lab-based saliva test on the market with more than 10 years of proven performance and over 15 million samples tested with accurate, reliable results.
OraSure Technologies Earnings Conference Call Invitation
GlobeNewswire - Tue Apr 22, 5:00AM CDT
2014 First Quarter Earnings Conference Call
Analyst Bullish On Medical Research, Equipment Stocks
at Investor's Business Daily - Tue Apr 08, 12:33PM CDT
A new analyst report from Cowen & Co. offers an upbeat assessment of medical research and equipment stocks ahead of first-quarter earnings, thanks to improving end markets. In his report on the Life Sciences and Diagnostic Tools sectors on Tuesday,...
OraSure Technologies Up 15.5% Since SmarTrend Uptrend Call (OSUR)
Comtex SmarTrend(R) - Fri Apr 04, 9:33AM CDT
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on February 18th, 2014 at $6.74. In approximately 2 month, OraSure Technologies has returned 15.52% as of today's recent price of $7.78.
OraSure Technologies' Debra Fraser-Howze Receives 2014 "Top Blacks in Healthcare" Award
GlobeNewswire - Fri Apr 04, 5:27AM CDT
OraSure Technologies, Inc. (Nasdaq:OSUR) is proud to announce that Debra Fraser-Howze, the Company's Senior Vice President of Government and External Affairs, received a 2014 "Top Blacks in Healthcare" Award from BlackDoctor.org in partnership with Johns Hopkins Center for Health Disparities Solutions.
4 Stocks Under $10 Moving Higher
at The Street - Fri Mar 28, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
OraSure Technologies Up 21.2% Since SmarTrend Uptrend Call (OSUR)
Comtex SmarTrend(R) - Thu Mar 27, 5:16PM CDT
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on February 18th, 2014 at $6.74. In approximately 1 month, OraSure Technologies has returned 21.16% as of today's recent price of $8.16.
SQI Diagnostics Signs Commercial Agreement with Global Pharma Customer
PR Newswire - Thu Mar 20, 2:26PM CDT
SQI to Develop Custom 21-Plex Protein Microarray for Drug Epitope Mapping -
OraSure Technologies Shares Up 18.6% Since SmarTrend's Buy Recommendation (OSUR)
Comtex SmarTrend(R) - Thu Mar 20, 11:13AM CDT
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on February 18th, 2014 at $6.74. In approximately 1 month, OraSure Technologies has returned 18.63% as of today's recent price of $7.99.
Uptrend Call Working As OraSure Technologies Stock Rises 19.2% (OSUR)
Comtex SmarTrend(R) - Thu Mar 13, 10:05AM CDT
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on February 18th, 2014 at $6.74. In approximately 3 weeks, OraSure Technologies has returned 19.23% as of today's recent price of $8.03.
Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and Financial Reports - Analyst Notes on Arrowhead, ANI, OraSure, Rigel, and Foundation Medicine
PR Newswire - Mon Mar 10, 11:30AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), OraSure Technologies, Inc. (NASDAQ: OSUR), Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Ways You Can Be a Better Health-Care Investor Than Warren Buffett
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 09, 1:03PM CDT
Behind only three other people on this planet -- Bill Gates, Carlos Slim, and Amancio Ortega -- stands Warren Buffett with $58.2 billion in accumulated wealth, according to Forbes ' latest rankings of the world's richest people. Buffett, perhaps...
Why OraSure Technologies, Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 05, 4:07PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of OraSure Technologies , a marketer of...
OraSure Technologies to Present at the Cowen & Company 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 26, 5:00AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. 34 Annual Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet.
OraSure Technologies to Present at the Raymond James 35th Annual Institutional Investors Conference
GlobeNewswire - Mon Feb 24, 5:12AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Raymond James 35 Annual Institutional Investors Conference in Orlando, Florida. The conference will be simultaneously webcast over the Internet.
